Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use USTEKINUMAB-AEKN safely and effectively. See full prescribing information for USTEKINUMAB-AEKN. USTEKINUMAB-AEKN injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 Ustekinumab-aekn is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of Ustekinumab-aekn has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to STELARA® (ustekinumab).
Medication labelWhy this: Advisory · dailymed-prescription
Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease. Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab-aekn
- product_names
- ustekinumab-aekn
- ndc
- 51759-709, 51759-709-32, 51759-710, 51759-710-32
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en